In tumour cells, the oncogene DLC1 tends to be inactivated, a process that not only upregulates the expression of FAK and talin, but also inhibits RhoA signalling, which in turn attenuates the contractility of the actin cytoskeleton [177]. The gene discussed is PTK2; the disease is neoplasm.